Table 5.
Summary of simulated ATV exposure measures at model-proposed pediatric ATV capsule doses boosted with RTV
| Body wt range (kg) | ATV/RTV dose (mg) |
Cmin |
Cmax |
AUC |
|||
|---|---|---|---|---|---|---|---|
| GM (ng/ml) | %a | GM (ng/ml) | %a | GM (ng·h/ml) | %a | ||
| 15 to <20 | 150/100 | 504 | 76.8 | 5,213 | 81.4 | 42,902 | 82.0 |
| 20 to <40 | 200/100 | 562 | 78.0 | 4,954 | 80.7 | 42,999 | 81.0 |
| ≥40 | 300/100 | 691 | 78.1 | 5,040 | 79.4 | 46,777 | 79.4 |
| Adult | 300/100 | 661 | 80 | 4,153 | 80 | 40,615 | 80 |
a
Percentage of pediatric subjects attaining exposures within the 10th and 90th percentiles of the target adult exposure at the adult label-recommended dose (ATV/RTV at 300/100 mg).